PMID- 32905618
OWN - NLM
STAT- MEDLINE
DCOM- 20210302
LR  - 20210302
IS  - 1099-1069 (Electronic)
IS  - 0278-0232 (Linking)
VI  - 39
IP  - 1
DP  - 2021 Feb
TI  - Recent advances in chimeric antigen receptor natural killer cell therapy for 
      overcoming intractable hematological malignancies.
PG  - 11-19
LID - 10.1002/hon.2802 [doi]
AB  - Natural killer (NK) cells have a potent cytotoxic activity against leukemia and 
      lymphoma without recognition of human leukocyte antigen (HLA) molecules. Chimeric 
      antigen receptor-engineered NK cells (CAR-NK cells) can be produced from the NK92 
      cell line, peripheral blood, cord blood, and induced pluripotent stem cells for 
      immunotherapy of malignant tumor cells. Recently, the safety and efficacy of 
      HLA-mismatched allogeneic cord blood-derived CD19 CAR-NK cell therapy for 
      CD19-positive hematological malignancies have been reported. However, the 
      durability of clinical effects has not been clarified. The characteristics of 
      CAR-NK cells with a strong antileukemia/lymphoma effect and better proliferative 
      capacity without severe adverse effects may be promising for overcoming 
      intractable hematological malignancies as an off-the-shelf allogeneic cellular 
      therapy.
CI  - (c) 2020 John Wiley & Sons Ltd.
FAU - Tanaka, Junji
AU  - Tanaka J
AUID- ORCID: 0000-0002-7026-1455
AD  - Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
LA  - eng
GR  - Ministry of Health, Labor and Welfare of Japan/
GR  - Mitsubishi Foundation/
PT  - Journal Article
PT  - Review
DEP - 20200921
PL  - England
TA  - Hematol Oncol
JT  - Hematological oncology
JID - 8307268
RN  - 0 (Receptors, Chimeric Antigen)
SB  - IM
MH  - *Hematologic Neoplasms/genetics/immunology/therapy
MH  - Humans
MH  - *Immunotherapy, Adoptive
MH  - *Killer Cells, Natural/immunology/transplantation
MH  - *Receptors, Chimeric Antigen/genetics/immunology
OTO - NOTNLM
OT  - CAR-NK cell
OT  - NK cell
OT  - cellular therapy
EDAT- 2020/09/10 06:00
MHDA- 2021/03/03 06:00
CRDT- 2020/09/09 18:16
PHST- 2020/06/11 00:00 [received]
PHST- 2020/07/29 00:00 [revised]
PHST- 2020/09/05 00:00 [accepted]
PHST- 2020/09/10 06:00 [pubmed]
PHST- 2021/03/03 06:00 [medline]
PHST- 2020/09/09 18:16 [entrez]
AID - 10.1002/hon.2802 [doi]
PST - ppublish
SO  - Hematol Oncol. 2021 Feb;39(1):11-19. doi: 10.1002/hon.2802. Epub 2020 Sep 21.